These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 28641106)

  • 1. Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases.
    Schoch KM; Miller TM
    Neuron; 2017 Jun; 94(6):1056-1070. PubMed ID: 28641106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
    Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
    Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides in therapy for neurodegenerative disorders.
    Evers MM; Toonen LJ; van Roon-Mom WM
    Adv Drug Deliv Rev; 2015 Jun; 87():90-103. PubMed ID: 25797014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotide therapy for neurodegenerative disease.
    Smith RA; Miller TM; Yamanaka K; Monia BP; Condon TP; Hung G; Lobsiger CS; Ward CM; McAlonis-Downes M; Wei H; Wancewicz EV; Bennett CF; Cleveland DW
    J Clin Invest; 2006 Aug; 116(8):2290-6. PubMed ID: 16878173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense technologies have a future fighting neurodegenerative diseases.
    Seidman S; Eckstein F; Grifman M; Soreq H
    Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):333-40. PubMed ID: 10463077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. The most effective target sites are clustered in double-stranded regions of the predicted secondary structure for the mRNA.
    Laptev AV; Lu Z; Colige A; Prockop DJ
    Biochemistry; 1994 Sep; 33(36):11033-9. PubMed ID: 8086420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Antisense Targeting of Huntingtin.
    Smith AV; Tabrizi SJ
    DNA Cell Biol; 2020 Feb; 39(2):154-158. PubMed ID: 31821021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides extend survival of prion-infected mice.
    Raymond GJ; Zhao HT; Race B; Raymond LD; Williams K; Swayze EE; Graffam S; Le J; Caron T; Stathopoulos J; O'Keefe R; Lubke LL; Reidenbach AG; Kraus A; Schreiber SL; Mazur C; Cabin DE; Carroll JB; Minikel EV; Kordasiewicz H; Caughey B; Vallabh SM
    JCI Insight; 2019 Jul; 5(16):. PubMed ID: 31361599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligonucleotide therapeutics in neurodegenerative diseases.
    Scoles DR; Pulst SM
    RNA Biol; 2018; 15(6):707-714. PubMed ID: 29560813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligonucleotide-based therapy for neurodegenerative diseases.
    Magen I; Hornstein E
    Brain Res; 2014 Oct; 1584():116-28. PubMed ID: 24727531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense applications for biological control.
    Pan WH; Clawson GA
    J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotides: treating neurodegeneration at the level of RNA.
    DeVos SL; Miller TM
    Neurotherapeutics; 2013 Jul; 10(3):486-97. PubMed ID: 23686823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.
    Bennett CF; Krainer AR; Cleveland DW
    Annu Rev Neurosci; 2019 Jul; 42():385-406. PubMed ID: 31283897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
    Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
    Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in therapeutic bacterial antisense biotechnology.
    Hegarty JP; Stewart DB
    Appl Microbiol Biotechnol; 2018 Feb; 102(3):1055-1065. PubMed ID: 29209794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.
    Mendonça MCP; Kont A; Aburto MR; Cryan JF; O'Driscoll CM
    Mol Pharm; 2021 Apr; 18(4):1491-1506. PubMed ID: 33734715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain.
    Mohan A; Fitzsimmons B; Zhao HT; Jiang Y; Mazur C; Swayze EE; Kordasiewicz HB
    Pain; 2018 Jan; 159(1):139-149. PubMed ID: 28976422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense Therapy for Infectious Diseases.
    Buthelezi LA; Pillay S; Ntuli NN; Gcanga L; Guler R
    Cells; 2023 Aug; 12(16):. PubMed ID: 37626929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects.
    Rigo F; Seth PP; Bennett CF
    Adv Exp Med Biol; 2014; 825():303-52. PubMed ID: 25201110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.